Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dade gives Abbott cardiac marker rights:

This article was originally published in Clinica

Executive Summary

Dade Behring has sublicensed to Abbott non-exclusive rights to use the emerging cardiac marker, placental growth factor (PlGF), in the development of tests for the diagnosis and prognosis of cardiovascular diseases. Studies have shown that levels of PlGF may be useful in the prognosis of acute coronary syndrome, a heart condition that impacts millions of people worldwide, said Deerfield, Illinois-based Dade.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel